S 3738
115th Congress
Senate
Health
Administrative remedies
Drug safety, medical device, and laboratory regulation
Fraud offenses and financial crimes
Intellectual property
Licensing and registrations
Prescription drugs
Securities
Hatch-Waxman Integrity Act of 2018
Introduced: December 11, 2018
See on congress.gov
Everywhere this bill has been
2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Dec 11, 2018
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Dec 11, 2018
Introduced in Senate
Plain-English summary
Hatch-Waxman Integrity Act of 2018
This bill amends the Federal Food, Drug, and Cosmetic Act and the Securities Exchange Act of 1934 to prevent a generic drug or biosimilar manufacturer from using a specific review process for challenging pharmaceutical drug or biologic patents.
What's happening now
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Committees of jurisdiction
1
Cosponsors
1